BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 20010944)

  • 1. Expression of aldehyde dehydrogenase 1 (ALDH1) is associated with basal-like markers and features of aggressive tumours in African breast cancer.
    Nalwoga H; Arnes JB; Wabinga H; Akslen LA
    Br J Cancer; 2010 Jan; 102(2):369-75. PubMed ID: 20010944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stem cell marker aldehyde dehydrogenase 1-positive breast cancers are characterized by negative estrogen receptor, positive human epidermal growth factor receptor type 2, and high Ki67 expression.
    Morimoto K; Kim SJ; Tanei T; Shimazu K; Tanji Y; Taguchi T; Tamaki Y; Terada N; Noguchi S
    Cancer Sci; 2009 Jun; 100(6):1062-8. PubMed ID: 19385968
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of aldehyde dehydrogenase 1 as a marker of mammary stem cells in benign and malignant breast lesions of Ghanaian women.
    Schwartz T; Stark A; Pang J; Awuah B; Kleer CG; Quayson S; Kingman S; Aitpillah F; Abantanga F; Jiagge E; Oppong JK; Osei-Bonsu E; Martin I; Yan X; Toy K; Adjei E; Wicha M; Newman LA
    Cancer; 2013 Feb; 119(3):488-94. PubMed ID: 22930220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic impact of the cancer stem cell related markers ALDH1 and EZH2 in triple negative and basal-like breast cancers.
    De Brot M; Rocha RM; Soares FA; Gobbi H
    Pathology; 2012 Jun; 44(4):303-12. PubMed ID: 22544210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences in expression of the cancer stem cell marker aldehyde dehydrogenase 1 among estrogen receptor-positive/human epidermal growth factor receptor type 2-negative breast cancer cases with early, late, and no recurrence.
    Miyoshi Y; Shien T; Ogiya A; Ishida N; Yamazaki K; Horii R; Horimoto Y; Masuda N; Yasojima H; Inao T; Osako T; Takahashi M; Tomioka N; Endo Y; Hosoda M; Doihara H; Miyoshi S; Yamashita H;
    Breast Cancer Res; 2016 Jul; 18(1):73. PubMed ID: 27368476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of aldehyde dehydrogenase 1 expression and biologically aggressive features in breast cancer.
    Kang EJ; Jung H; Woo OH; Park KH; Woo SU; Yang DS; Kim AR; Lee JB; Kim YH; Kim JS; Seo JH
    Neoplasma; 2014; 61(3):352-62. PubMed ID: 24824938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High expression of stem cell marker ALDH1 is associated with reduced BRCA1 in invasive breast carcinomas.
    Madjd Z; Ramezani B; Molanae S; Asadi-Lari M
    Asian Pac J Cancer Prev; 2012; 13(6):2973-8. PubMed ID: 22938492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Co-expression of stem cell markers ALDH1 and CD44 in non-malignant and neoplastic lesions of the breast.
    DA Cruz Paula A; Marques O; Rosa AM; DE Fátima Faria M; Rêma A; Lopes C
    Anticancer Res; 2014 Mar; 34(3):1427-34. PubMed ID: 24596390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aldehyde dehydrogenase 1 expression in inflammatory breast cancer as measured by immunohistochemical staining.
    Gong Y; Wang J; Huo L; Wei W; Ueno NT; Woodward WA
    Clin Breast Cancer; 2014 Jun; 14(3):e81-8. PubMed ID: 24461456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical-pathologic significance of cancer stem cell marker expression in familial breast cancers.
    Bane A; Viloria-Petit A; Pinnaduwage D; Mulligan AM; O'Malley FP; Andrulis IL
    Breast Cancer Res Treat; 2013 Jul; 140(1):195-205. PubMed ID: 23813303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aldehyde dehydrogenase 1/epidermal growth factor receptor coexpression is characteristic of a highly aggressive, poor-prognosis subgroup of high-grade serous ovarian carcinoma.
    Liebscher CA; Prinzler J; Sinn BV; Budczies J; Denkert C; Noske A; Sehouli J; Braicu EI; Dietel M; Darb-Esfahani S
    Hum Pathol; 2013 Aug; 44(8):1465-71. PubMed ID: 23465277
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of ALDH1A1 in contributing to breast tumour aggressiveness: A study conducted in an African population.
    Gyan E; Green A; Ahenkorah-Fondjo L; Jackson A; Toss MS; Akakpo PK; Derkyi-Kwarteng L; Rahman GA; Owiredu W
    Ann Diagn Pathol; 2021 Apr; 51():151696. PubMed ID: 33460998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of ALDH1 and TGFβ2 in benign and malignant breast tumors and their prognostic implications.
    Zheng R; Wang J; Wu Q; Wang Z; Ou Y; Ma L; Wang M; Wang J; Yang Y
    Int J Clin Exp Pathol; 2014; 7(7):4173-83. PubMed ID: 25120797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ALDH1 expression correlates with favorable prognosis in ovarian cancers.
    Chang B; Liu G; Xue F; Rosen DG; Xiao L; Wang X; Liu J
    Mod Pathol; 2009 Jun; 22(6):817-23. PubMed ID: 19329942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Androgen Receptor and ALDH1 Expression Among Internationally Diverse Patient Populations.
    Jiagge E; Jibril AS; Davis M; Murga-Zamalloa C; Kleer CG; Gyan K; Divine G; Hoenerhoff M; Bensenhave J; Awuah B; Oppong J; Adjei E; Salem B; Toy K; Merajver S; Wicha M; Newman L
    J Glob Oncol; 2018 Oct; 4():1-8. PubMed ID: 30307804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ALDH1 is a better clinical indicator for relapse of invasive ductal breast cancer than the CD44+/CD24- phenotype.
    Zhong Y; Shen S; Zhou Y; Mao F; Guan J; Lin Y; Xu Y; Sun Q
    Med Oncol; 2014 Mar; 31(3):864. PubMed ID: 24519209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of stem cell and epithelial-mesenchymal transition markers in primary breast cancer patients with circulating tumor cells.
    Kasimir-Bauer S; Hoffmann O; Wallwiener D; Kimmig R; Fehm T
    Breast Cancer Res; 2012 Jan; 14(1):R15. PubMed ID: 22264265
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Independent prognostic value of the basal-like phenotype of breast cancer and associations with EGFR and candidate stem cell marker BMI-1.
    Arnes JB; Collett K; Akslen LA
    Histopathology; 2008 Feb; 52(3):370-80. PubMed ID: 18269588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of aldehyde dehydrogenase 1 (ALDH1) in invasive breast carcinomas.
    Demir H; Dulgar O; Gulle BT; Turna H; Ilvan S
    Bosn J Basic Med Sci; 2018 Nov; 18(4):313-319. PubMed ID: 29924962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aldehyde dehydrogenase 1 expression predicts poor prognosis in triple-negative breast cancer.
    Ohi Y; Umekita Y; Yoshioka T; Souda M; Rai Y; Sagara Y; Sagara Y; Sagara Y; Tanimoto A
    Histopathology; 2011 Oct; 59(4):776-80. PubMed ID: 22014057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.